» Articles » PMID: 25869442

Genomic Instability in Human Cancer: Molecular Insights and Opportunities for Therapeutic Attack and Prevention Through Diet and Nutrition

Abstract

Genomic instability can initiate cancer, augment progression, and influence the overall prognosis of the affected patient. Genomic instability arises from many different pathways, such as telomere damage, centrosome amplification, epigenetic modifications, and DNA damage from endogenous and exogenous sources, and can be perpetuating, or limiting, through the induction of mutations or aneuploidy, both enabling and catastrophic. Many cancer treatments induce DNA damage to impair cell division on a global scale but it is accepted that personalized treatments, those that are tailored to the particular patient and type of cancer, must also be developed. In this review, we detail the mechanisms from which genomic instability arises and can lead to cancer, as well as treatments and measures that prevent genomic instability or take advantage of the cellular defects caused by genomic instability. In particular, we identify and discuss five priority targets against genomic instability: (1) prevention of DNA damage; (2) enhancement of DNA repair; (3) targeting deficient DNA repair; (4) impairing centrosome clustering; and, (5) inhibition of telomerase activity. Moreover, we highlight vitamin D and B, selenium, carotenoids, PARP inhibitors, resveratrol, and isothiocyanates as priority approaches against genomic instability. The prioritized target sites and approaches were cross validated to identify potential synergistic effects on a number of important areas of cancer biology.

Citing Articles

Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).

Smolarz B, Lukasiewicz H, Samulak D, Piekarska E, Kolacinski R, Romanowicz H Int J Mol Sci. 2025; 26(5).

PMID: 40076671 PMC: 11900952. DOI: 10.3390/ijms26052049.


Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.

Baumann A, Buribayev Z, Wolkenhauer O, Salybekov A, Wolfien M Epigenomes. 2025; 9(1).

PMID: 39982247 PMC: 11843950. DOI: 10.3390/epigenomes9010005.


Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.


Cancer genetics and deep learning applications for diagnosis, prognosis, and categorization.

Sokouti M, Sokouti B J Biol Methods. 2024; 11(3):e99010017.

PMID: 39544183 PMC: 11557296. DOI: 10.14440/jbm.2024.0016.


From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.

Gharib E, Robichaud G Int J Mol Sci. 2024; 25(17).

PMID: 39273409 PMC: 11395697. DOI: 10.3390/ijms25179463.


References
1.
Kee Y, DAndrea A . Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010; 24(16):1680-94. PMC: 2922498. DOI: 10.1101/gad.1955310. View

2.
Zhang J, Kan Y, Tian Y, Wang Z, Zhang J . Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells. Indian J Med Res. 2013; 137(3):527-32. PMC: 3705661. View

3.
Bajpai S, Mishra M, Kumar H, Tripathi K, Singh S, Pandey H . Effect of selenium on connexin expression, angiogenesis, and antioxidant status in diabetic wound healing. Biol Trace Elem Res. 2011; 144(1-3):327-38. DOI: 10.1007/s12011-011-9097-7. View

4.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

5.
Peel N, Stevens N, Basto R, Raff J . Overexpressing centriole-replication proteins in vivo induces centriole overduplication and de novo formation. Curr Biol. 2007; 17(10):834-43. PMC: 1885955. DOI: 10.1016/j.cub.2007.04.036. View